@_CTGCT_i
iAccount based inSlovenia
About this account
- Account based in
- Slovenia
- Connected via
- Poland Android App
Account-level information from X, not a live location or the device used for a specific post.
Co-funded by the European Union, the UK Research and Innovation and European Regional Development Fund EU under Slovenia’s Cohesion Policy Programme 2021-2027
Ljubljana, Slovenia
Joined March 2024
- Tweets311
- Following1.2K
- Followers260
- Likes683
Can we control cells with pulses of light?💡
The 2026 #NobelPrize #Medicine honors #optogenetics, it changed neuroscience and is now shaping synthetic biology, regenerative medicine, and gene & cell therapies.
What else can be used to control them?👀
ctgct.si/en/objave/impact-op…
How do you take a gene therapy for an ultra-rare disease from concept to clinical trial?
Our latest article based on the lecture of @DuskoLainscek explores the development of URBAGEN for CTNNB1 syndrome and the challenges behind AAV-based therapies. 👇
ctgct.si/en/objave/advancing…
The story is not only about vector design. It includes patient-derived organoids, animal studies, biodistribution, toxicology, GMP manufacturing, dose selection, and years of regulatory preparation before the first patients can be treated.
#GeneTherapy #AAV #CTNNB1 #RareDiseases
#URBAGEN also highlights a broader challenge: how do we develop therapies for diseases affecting only a few hundred people worldwide? Read the full article and meet Duško Lainšček at #CTGCTDay2026 to continue the discussion.
#CellAndGeneTherapy #AdvancedTherapies
Sebastian Diecke of the @MDC_Berlin is joining #CTGCTDay2026 as an invited speaker.
Hear his insights on pluripotent stem cell technologies and connect with the cell and gene therapy community.
Registration is free this year, so secure your place: forms.cloud.microsoft/e/inxv…
📢 Deadline day is here!
Abstract submissions for #CTGCTDay2026 close today.
Don't miss the opportunity to present your work and connect with researchers across the gene and cell therapy field.
🔗 Submit your abstract: forms.cloud.microsoft/e/NdYJ…
@kemijski @UCLTRO @UMCU_Intl
At #CaringForRare2026, one message was clear: progress in rare diseases happens when researchers, clinicians and patients work together.
CTGCT's @gcuzak joined discussions to advance gene & cell therapies.
Read more: ctgct.si/en/objave/ctgct-car…
📢 Last call!
Only 3 days left to submit your abstract for #CTGCTDay2026 and showcase your work to the gene and cell therapy community.
📅 Deadline: 30 September 2026
🔗 forms.cloud.microsoft/e/NdYJ…
#ResearchConference @kemijski @UCLTRO @UMCU_Intl @ChariteBerlin @tudresden_de
CTGCT retweeted
Excellent science is not enough.
In our new #GeneH video, partners discuss what must change for #GeneTherapy research to
move closer to patients: regulation, manufacturing, funding, clinical pathways and stronger
collaboration.
Watch: youtu.be/KIc-uUvwjBs
#ResearchToPatients
📢 Abstract submission closes in 7 days!
Researchers, students, and professionals: this is your chance to present your work at #CTGCTDay2026.
📅 Deadline: 30 September 2026
🔗 Submit your abstract: forms.cloud.microsoft/e/NdYJ…
#GeneTherapy #CellTherapy #LifeSciences
Another confirmed speaker for #CTGCTDay2026!
We’re pleased to welcome Jan Procházka from the Czech Centre for Phenogenomics, whose work spans functional genomics, rare genetic diseases & preclinical research.
✅ Submit your abstract
✅ Register to attend
ctgct.si/en/ctgct-day-2026/
How can a skin cell become a #StemCell capable of forming heart cells, neurons, or organoids?
Our colleague Darja Marolt Presen explored the science and challenges behind iPSC technology during a workshop with @BESTLjubljana.
Read more: ctgct.si/en/objave/ipsc-pres…
#iPSC #CTGCT
The #CTGCTDay2026 abstract deadline has been extended to 30 September 2026.
📅11 November
📍Ljubljana
⚠️ Only 50 seats left
Submit your abstract and register: ctgct.si/en/ctgct-day-2026/
@kemijski @UCLTRO @UMCU_Intl @tudresden_de @ChariteBerlin @GeneH_project #GeneTherapy #Cancer
CAR-T therapy is an example of a "living medicine". How do engineered immune cells recognize and destroy cancer cells, and what challenges remain before these therapies become more widely accessible?
Link: ctgct.si/en/objave/living-me…
#CART #Immunotherapy #CancerResearch @kemijski
Present your research at #CTGCTDay2026!
Submit your abstract by 15 September and join confirmed speaker Petra Sušjan, Research Associate in Synthetic Biology and Immunoly department of the @kemijski.
Details: ctgct.si/en/ctgct-day-2026/
David Morrow, Scientific Lead for #AdvancedTherapies at #EATRIS, is a confirmed speaker at #CTGCTDay2026!
Working in gene and cell therapy or related fields?
✅ Submit your abstract before 15th September
✅ Register to attend
Link: ctgct.si/en/ctgct-day-2026
#GeneAndCellTherapy
#CRISPR editors are getting more powerful. The challenge? Getting them to the right cells.
In this article, we break down the delivery technologies for CRISPR, based on the review by Tjaša Lapanja, @DuskoLainscek, and colleagues.
Link: ctgct.si/en/objave/challenge…
#CTGCT @kemijski
Today we're hosting more than 30 students from across Europe at @kemijski, in collaboration with @BESTLjubljana.
They are learning about #CART therapies, #iPSCs, #AAV-based gene therapy, viral vector manufacturing, regulatory aspects, and the #CTGCT and @GeneH_project projects.
We're pleased to welcome Associate Professor @DuskoLainscek (@kemijski ) to this year's programme.
✅ Submit your abstract
✅ Register to attend
Join the discussion: ctgct.si/en/ctgct-day-2026/
#GeneAndCellTherapy #CTGCTDay2026 #GeneAndCellTherapy #GCT #CTGCT
Registration is now open for #CTGCTDay2026:
Connect with leaders from academia, clinical research, industry, and more discussing the next generation of cell, tissue, and gene therapies.
📍 Ljubljana, Slovenia
🎟️Link: ctgct.si/en/ctgct-day-2026/
📝 Abstract submission: 15 September